Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $193 |
| Triangulated Fair Value | $169 |
| 12-mo Scenario PWEV | $193 |
| Implied Return | -13% |
| Forward P/E | 15.0x |
| Market Cap | $32B |
| 52-Week Range | $154 – $247 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $341, +77% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($193) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Biopharma-Funding / China / Bioprocessing Reset' (20%) — targets $85, -56% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 48% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.62 vs analyst floor +0.00 → delta +0.62 (n=12 mgmt / 6 Q&A; 90th pctile across the S&P book, z +1.4).
Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.62 | +0.00 | +0.62 |
| 2025Q4 | +0.43 | +0.00 | +0.43 |
| 2025Q3 | +0.27 | +0.15 | +0.12 |
| 2025Q2 | +0.31 | +0.24 | +0.07 |
News (last 365d, 1000 articles): avg ticker sentiment +0.21 (bullish 32% / bearish 4%)
Scenario Analysis
The tree runs from a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($85) to a 'Bull — Re-Rate' bull case ($341); the probability-weighted blend (PWEV $193) is -0% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Biopharma-Funding / China / Bioprocessing Reset | 20% | $85 | -56% |
| R&D-Spend Recession | 17% | $144 | -25% |
| Base — Tools + Services Growth | 35% | $200 | +4% |
| Growth — Bioprocessing / Biologics Recovery | 20% | $270 | +40% |
| Bull — Re-Rate | 8% | $341 | +77% |
| Probability-Weighted (PWEV) | — | $193 | -0% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $85). Structural impairment — biopharma-funding / China / bioprocessing reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 84.81; probability: 0.2.
- R&D-Spend Recession (17%, $144). Cyclical downturn — biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding weakens for 1–2 years before normalising. Drivers — implied_target: 144.02; probability: 0.17.
- Base — Tools + Services Growth (35%, $200). Mid-cycle — normalised biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding; disciplined capital allocation; steady returns. Drivers — implied_target: 200.03; probability: 0.35.
- Growth — Bioprocessing / Biologics Recovery (20%, $270). Upside — bioprocessing + biologics recovery lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 270.04; probability: 0.2.
- Bull — Re-Rate (8%, $341). Upside tail — sustained tight conditions or a structural re-rate on bioprocessing + biologics recovery. Drivers — implied_target: 341.05; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $171 | -12% |
| Peer P/E re-rate | multiple | $291 | +50% |
| Peer EV/Revenue re-rate | multiple | $489 | +153% |
| Scenario PWEV | multiple | $193 | -0% |
| DCF (5-year + terminal) | cash flow + terminal × | $116 | -40% |
| Triangulated (weighted) | — | $169 | -13% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $171 and 40% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (48% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 13x terminal FCF multiple → $116. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 22.625x) implies $291. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Life-Science Tools & Services | $16.6B | 100% | 6% | 15% | 15x | 5% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding |
| net_debt_or_cash_b | -14.12 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | None |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | biopharma-funding / China / bioprocessing reset |
| upside | bioprocessing + biologics recovery |
Industry Context — Health Devices Tools
This name sits in the Health Devices Tools as a life_science_tools. biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Funding / Utilization Reset | 37% | 37% | |
| Mid-Cycle — Procedure & R&D Demand | 35% | 35% | |
| Upside — Innovation / Recovery Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $18B | $3B | $1B | $1B | $2B | $2B |
| FY+2 | $19B | $3B | $1B | $1B | $2B | $2B |
| FY+3 | $20B | $3B | $1B | $1B | $3B | $2B |
| FY+4 | $20B | $3B | $1B | $1B | $3B | $2B |
| FY+5 | $21B | $3B | $1B | $1B | $3B | $2B |
| Terminal | — | — | — | — | $3B × 13x | $24B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $10B + PV(terminal) $24B = EV $33B; + net cash → equity $19B ÷ diluted shares 0.17B = $116/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $160/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 12% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| TMO | 4.93x | 19.72x | 6% | 18% |
| DHR | 6.03x | 22.88x | 6% | 23% |
| A | 5.51x | 22.37x | 6% | 24% |
| WAT | 10.97x | 25.58x | 6% | 3% |
| Median | 5.77x | 22.625x | — | — |
Peer-median fwd P/E → $291; EV/Rev → $489.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $116 | 41% | $48 |
| Scenario PWEV | $193 | 29% | $57 |
| Monte Carlo median | $171 | 18% | $30 |
| Peer P/E | $291 | 12% | $34 |
| Triangulated | — | 100% | $169 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 9.1x | 11.0x | 13.0x | 14.9x | 16.9x |
|---|---|---|---|---|---|
| 6% | $86 | $109 | $133 | $156 | $179 |
| 8% | $80 | $101 | $124 | $146 | $168 |
| 8% | $73 | $94 | $116 | $136 | $158 |
| 10% | $67 | $87 | $108 | $128 | $148 |
| 10% | $62 | $80 | $100 | $119 | $139 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $61 | $78 | $95 | $113 | $130 |
| -1.5pp | $69 | $87 | $105 | $124 | $142 |
| +0.0pp | $77 | $96 | $116 | $135 | $154 |
| +1.5pp | $85 | $106 | $127 | $147 | $168 |
| +3.0pp | $94 | $116 | $138 | $160 | $182 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $77 | $154 | $77 |
| Terminal × ±15% | $94 | $137 | $42 |
| Revenue CAGR ±3pp | $95 | $138 | $42 |
| WACC ±1pp | $108 | $124 | $16 |
| FCF conversion ±10% | $116 | $116 | $0 |
Company lever — SoP/share vs Life-Science Tools & Services multiple (AI re-rating) (base 15x)
| Multiple | 10.5x | 12.8x | 15.0x | 17.2x | 19.5x |
|---|---|---|---|---|---|
| SoP/share | $959 | $1,188 | $1,406 | $1,625 | $1,854 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 13×, FY+5 revenue $21B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $85.
Fact / Inference / Speculation
- FACT: Spot $193; 52-week range $154–$247; engine rating HOLD; base-case target $193 (-0%).
- INFERENCE: Triangulated FV $169 (-13%). Gross Margin explains 48% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 48% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $169 (-13% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (48% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).